002004 Huapont Life Sciences
- 4.68
- +0.04+0.86%
Huapont Life Sciences News
Huabang Health (002004.SZ): No related products are involved in synthetic biology
Gelonghui, May 10 | Huabang Health (002004.SZ) said on the investor interactive platform that in terms of synthetic biology, the company has not yet involved related products, but the company will actively experiment with synthetic biology technology and keep a close eye on related policy developments. In terms of stem cells, the company's shareholders are involved in related businesses: 1. Hebei Life Origin Biotechnology Co., Ltd. is the builder and operator of the Hebei Stem Cell Bank. Its core business is cell storage business such as neonatal stem cells, adult immune cells, etc., and clinical research and application transformation of stem cell products. 2. Jiangsu Puxin Biomedical Co., Ltd. is mainly engaged in cell and gene therapy
Huabang Health (002004.SZ) announced first-quarter results, net profit of 156 million yuan, a decrease of 12.18%
Huabang Health (002004.SZ) released its report for the first quarter of 2024. During the reporting period, it achieved revenue of 2,915 billion yuan, a year-on-year decrease of 2.02%. Net profit attributable to shareholders of listed companies was 156 million yuan, a year-on-year decrease of 12.18%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 149 million yuan, a year-on-year decrease of 11.79%.
Huabang Health (002004.SZ): The holding subsidiary Kaisheng New Materials is mainly engaged in R&D, production and sales of fine chemical products and new polymer materials
Gelonghui, March 13 | Huabang Health (002004.SZ) said on the investor interactive platform that the company's holding subsidiary Kaisheng New Materials is mainly engaged in R&D, production and sales of fine chemical products and novel polymer materials. The business covers inorganic chemicals, carboxyl chlorides, hydroxychlorides, and the novel polymer material polyether ketone. The main products include inorganic chemicals (including sulfoxide chloride and sulfuryl chloride), carboxyl chloride (including aramid polymer monomers, para-nitrobenzoyl chloride, chloroacetyl chloride, etc.), hydroxychlorides (including chloroacetyl chloride, etc.), hydroxychlorides (including chloroacetyl chloride, etc.), hydroxy chlorides (including chloroacetyl chloride, etc.), and polychlorochlorides (including polychlorinated polymers) ether ketone ketone, etc.
Huabang Health (002004.SZ): Controlling shareholders pledge 4.3 million shares
Gelonghui, Feb. 7 | Huabang Health (002004.SZ) announced that the company recently received a notice from Xizang Huibang Technology Co., Ltd. (“Huibang Technology”), the holding stock of the company, and learned that it will pledge some of the company's shares. The number of shares pledged this time is 4.3 million shares.
Express News | More than 10 listed companies announced additional shareholders' pledges after the market, 20 companies interacted easily to respond to whether there is a risk of stock pledges
Huabang Health (002004.SZ): A total cost of 15.27 million yuan to buy back 3.355,800 shares
Gelonghui, Feb. 1 | Huabang Health (002004.SZ) announced that as of January 31, 2024, the company had repurchased a total of 33558.08 million shares through centralized trading, accounting for 0.17% of the company's current total share capital. The highest transaction price was 4.65 yuan/share, the lowest transaction price was 4.23 yuan/share, and the total amount paid was 15.027 million yuan (not including transaction fees).
Huabang Health (002004.SZ): As of the end of the third quarter of 2023, the company's travel sector revenue exceeded 900 million yuan
Gelonghui, January 17 | Huabang Health (002004.SZ) said on the investor interactive platform that the company's tourism resources are widely distributed in various 5A scenic spots in Yunnan, Shaanxi, Chongqing, Guangxi, etc., and its business covers scenic ropeway transportation, hotel management, tourism and entertainment. By the end of the third quarter of 2023, the company's travel sector had revenue of over 900 million yuan.
Huabang Health (002004.SZ): Initial repurchase of 870,000 shares involving 4,023,800 yuan
Gelonghui, January 8, 丨 Huabang Health (002004.SZ) announced that on January 8, 2024, the company implemented the first repurchase. According to relevant regulations, the implementation status is now announced as follows: the number of shares repurchased by the company for the first time through centralized bidding transactions is 870,000 shares, accounting for 0.04% of the company's total share capital, minimum transaction price 4.61 yuan/share, maximum transaction price 4.64 yuan/share, and the total repurchase amount paid is 4,023,800 yuan (excluding transaction fees such as commissions and transfer fees).
Huabang Health (002004.SZ): Prescription drugs such as adapalene gel and tretinoin cream produced have a certain effect on treating acne pits
Gelonghui, January 4 | Huabang Health (002004.SZ) said on the investor interactive platform that prescription drugs such as adapalene gel and tretinoin cream produced by the company have certain effects on acne pits treatment. It is recommended that you seek advice and guidance from a professional doctor. It is recommended that you seek advice and guidance from a doctor based on factors such as the type, severity and skin condition of the acne pits, and use the medication according to doctor's instructions. In addition, in terms of functional skincare products, the azelaic acid series products launched by the company's Sanrui brand have a certain auxiliary effect on the recovery of acne pits. Related products can be searched on Taobao's “Huabang Pharmaceutical Sanrui Skincare Store”, Tmall's “Sanrui Cosmetics Flagship Store”, and Beijing
Huabang Health (002004.SZ): Plans to spend 20 million yuan to 30 million yuan to buy back the company's shares
On December 27, Gelonghui | Huabang Health (002004.SZ) announced an announcement on the plan to repurchase the company's shares. The total capital of this repurchase is not less than RMB 20 million (inclusive) and not more than RMB 30 million (inclusive). The repurchase price is not higher than RMB 7.21 per share. Equity incentive plans or employee stock ownership plans for repurchase purposes. According to the maximum repurchase amount and maximum repurchase price, the estimated number of shares that can be repurchased is about 4,160,888 shares, accounting for 0.21% of the current total share capital of the company; based on the lower repurchase amount and upper repurchase price, the estimated number of shares that can be repurchased is approximately
Huabang Health: The controlling shareholder proposed to repurchase shares for 20 million yuan to 30 million yuan
Glonghui December 10 | Huabang Health announced that the controlling shareholder proposed to repurchase shares at 20 million yuan to 30 million yuan. The upper limit of the share repurchase price is not higher than 7.29 yuan.
Huabang Health (002004.SZ): A novel nanoantibody drug for psoriasis is being developed and is currently in the pre-clinical research stage
Glonghui, December 4, Huabang Health (002004.SZ) said on an interactive platform that for a long time, the company has set up 3-5 products on a rolling basis every year to ensure product iteration and new product research and development, thus achieving full coverage of dermatologic drugs. In terms of innovative drugs, the company and participating company Pregin are collaborating to develop a novel nanoantibody drug to treat psoriasis, which is currently in the pre-clinical research stage.
Huabang Health (002004.SZ): Has supplied high-purity battery-grade sulfoxide chloride to some electrolyte manufacturers
Glonghui November 20 | Huabang Health (002004.SZ) recently stated at an online investor reception day event that compared to ordinary industrial grade, battery-grade sulfoxide chloride has higher purity and fewer impurities and content. Since lithium bifluorosulfonimide (LiFSi) products have not yet been scaled up on a large scale, battery grade sulfoxide currently accounts for a small proportion of total sulfoxide chloride shipments. In the future, with the gradual release of LiFSI products, demand for battery-grade sulfoxide chloride will gradually increase. Currently, the company has a production capacity of 150,000 tons/year of sulfoxide chloride, and has supplied high-purity battery-grade chlorine to some electrolyte manufacturers
Huabang Health (002004.SZ): Kaisheng New Materials currently has a production capacity of 31,000 tons/year for aramid monomers
Glonghui November 20 | Huabang Health (002004.SZ) recently stated at an online investor reception day event that the lower sales price of sulfoxide chloride products this year is mainly related to raw material procurement prices and sluggish demand in the downstream pesticide market, and is cyclical to a certain extent. Kaisheng New Materials, a holding subsidiary of the company, will firmly implement the one-chain, two-wing development strategy. Based on the sulfoxide chloride industry chain, it will continue to develop new applications and products downstream, thereby increasing the added value of sulfoxide chloride derivatives. Kaisheng New Materials currently has a production capacity of 31,000 tons/year for aramid monomers, and is also raising capital to build new production capacity to meet customer expectations
Huabang Health (002004.SZ): Its tourism companies, led by Lijiang Co., Ltd., have clearly recovered
Glonghui November 20 | Huabang Health (002004.SZ) recently stated at an online investor reception day event that since this year, the domestic travel market has been picking up overall, and the company's tourism enterprises, led by Lijiang Co., Ltd., have clearly recovered, and the number of visitors has increased significantly compared to the same period last year. In the future, the company will strive to improve the quality of tourist services, focus on marketing and promotion efforts, actively improve the company's business vitality, and bring visitors a more comfortable, convenient and satisfying experience.
Huabang Health (002004.SZ): Beijing Huasheng Rehabilitation Hospital is still in the early stages of development
Glonghui November 7 | Huabang Health (002004.SZ) said on the investor interactive platform that Beijing Huasheng Rehabilitation Hospital is currently still in the early stages of development. Since the official launch of health insurance services in September 2022, the number of patients has continued to rise, and the operation is good. Please stay tuned to the company's regular reports on related situations.
Huabang Health (002004.SZ)'s net profit for the third quarter was 118 million yuan, a year-on-year decrease of 25.03%
On October 30, Huabang Health (002004.SZ) announced its report for the third quarter of 2023. From July to September 2023, operating income was 2,984 billion yuan, down 14.28% year on year; net profit attributable to shareholders of listed companies was 118 million yuan, down 25.03% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 107 million yuan, down 25.65% year on year, with basic earnings per share of 0.0595 yuan.
Huabang Health (002004.SZ): No drugs related to hepatitis have been involved
Glonghui, October 13丨Huabang Health (002004.SZ) said on the investor interactive platform, “Hello investors. The company has been deeply involved in the skin industry for 30 years and is a leading enterprise in the field of clinical skin medication and skin health in China. Currently, the company is not involved in hepatitis related drugs.
Huabang Health (002004.SZ): No diet medicine products have been involved
Glonghui, Oct. 12, 丨 Huabang Health (002004.SZ) said on the investor interactive platform that the company has been deeply involved in the skin industry for 30 years and is a leading enterprise in the field of clinical skin medication and skin health in China. Currently, the company is not involved in diet medicine products.
Qinling Tourism, a company listed on the New Third Board under Huabang Health, plans to be listed separately
GLONGHUI September 2 | Qinling Tourism, a holding subsidiary listed on the New Third Board of Huabang Health, plans to transfer to a separate listing. Earlier, Zhang Hai'an, general manager of Huabang Health, publicly stated that as the Taibai Mountain Scenic Area continues to mature and passenger traffic continues to increase, the possibility of Qinling Tourism going public in the future will not be ruled out.
Analysis
Price Target
No Data
